Dave Payne Email Address

EUCAN Strategic Launch Lead

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio, Indivior has a strong pipeline of product candidates designed to both expand treatments in opioid dependence and address other chronic diseases of addiction - including alcohol use disorder, cocaine intoxication and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio is available in over 40 countries worldwide. Its name is a fusion of the words individual and endeavor and its logo radiates the company's patient-centered holistic focus on expanding access to high-quality treatment services for addiction worldwide.

Business Unit Director responsible for UK/Ire operations of the current addictions business and future pipeline products. Previously Sales and Marketing Manager, leading and owning the development, translation and implementation of localised strategy in the field of heroin addiction. Line management of UK KAM team, HDM team, commercial manager and Sales and Marketing associate. Previous extensive experience in gastroenterology, Multiple Myeloma, Myelodysplastic Syndromes and Acute Myeloid Leukaemia resulting in expertise large crowded market places and in the field of orphan/rare diseases. A driven and focused individual who has delivered exceptional results in a complex and intensely competitive marketplace. A clear-headed strategic thinker who is able to translate brand strategy into effective tactics in order to achieve business goals. Expertise in branding and positioning with well-rounded experience in all areas of the brand life-cycle from launch to loss of exclusivity. Commercial Final signatory.